How Nu-V3 Delivers Neuromodulation
The micro-signal produced by the Nu-V3 device is delivered to the cranial nerves as a 'pulsed stimulation', traveling through the brain, brain stem and hypothalamus, accessing the autonomic nervous system at the strength and frequency shown to create the least amount of resistance.
These cranial nerves, particularly the vagus nerve, the trigeminal nerve and the glossopharyngeal nerve, are accessed non-invasively by the Nu-V3 device, which is worn comfortably on the ear.
Because the patient is able to wear Nu-V3 24/7, treatment is provided uninterrupted over the length of the Nu-V3 treatment program.
Nu-V3 functions non-invasively and non-pharmaceutically
The Business of Neuromodulation Technologies
Over the years, the global healthcare industry has witnessed a paradigm shift, and is now increasingly focused on minimally invasive therapies that not only treat a wide range of chronic and refractory disorders but also have fewer side effects. The demand for neuromodulation has increased significantly, due to patients’ preference for minimally invasive forms of treatment. Moreover, these minimal or non-invasive therapies allow physicians or patients to cease treatment, as and when required, by simply removing the stimulating devices, unlike implanted, invasive devices.
Based on technology, the internal neuromodulation category has been the largest and fastest-growing component category since 2015. In the internal neuromodulation category, the spinal cord stimulation segment was expected to dominate the neuromodulation market. However, the deep brain stimulation segment is expected to grow at the highest CAGR through 2020. In the external neuromodulation category, the transcutaneous electrical nerve stimulation segment is expected to be the largest segment in the neuromodulation market. However, the transcranial magnetic stimulation segment has registered the highest CAGR as of 2020.
An Explanation of Neuromodulation Technologies - Device and Pharmaceutical
Transcutaneous electrical nerve stimulation (TENS) is a non-invasive approach that came into use in the 1970s and may inhibit pain signals by stimulating areas beneath the skin. TENS is approved to be used at the location where pain exists and should not be confused with cranial nerve stimulation (CES), which involves stimulation of the cranial nerves on or around the area of the head and brain. TENS typically operates at a significantly higher frequency.
In the past 5 years, new antiepileptic drugs have been approved for clinical use. Some of these drugs have unique, novel mechanisms of action. Overall efficacy of these agents, however, seems similar to other antiepileptic drugs. Vagus nerve stimulation is a well-established palliative therapy for medically resistant epilepsy. Neurostimulation, with newer devices and targets becoming available, is a rapidly expanding field in epileptology.
Deep brain stimulation involves implanting electrodes within certain areas of your brain. These electrodes produce electrical impulses that regulate abnormal impulses. Or the electrical impulses can affect certain cells and chemicals within the brain.
The amount of stimulation in deep brain stimulation is controlled by a pacemaker-like device placed under the skin in your upper chest. A wire that travels under your skin connects this device to the electrodes in your brain.
Transcranial magnetic stimulation (TMS) is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. TMS is typically used when other depression treatments haven't been effective. This treatment for depression involves delivering repetitive magnetic pulses, so it's called repetitive TMS or rTMS. While TMS is non-invasive, it is not mobile.
A spinal cord stimulator (SCS) device is surgically placed under the skin and sends a mild electric current to the spinal cord. Spinal cord stimulation therapy masks pain signals before they reach the brain. A small device, similar to a pacemaker, delivers electrical pulses to the spinal cord, helping people to better manage their chronic pain and reduce their use of opioid medication.
The Nu-V3 treatment program utilizes the science of neuromodulation combined with a comprehensive treatment program which follows the patient through the treatment, maintenance and aftercare phases. Nu-Life utilizes supportive technology such as heart rate variability, telemedicine and patient-first results software to provide the best opportunity for long term benefit.
What sets Nu-V3 apart from the rest?
No negative side effects
Long term relief